Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diphemanil (commonly used as its salt, diphemanil methylsulfate) is a quaternary ammonium anticholinergic drug. It acts primarily as an antagonist at muscarinic acetylcholine receptors, especially the M3 subtype. By blocking these receptors, it decreases secretory excretion of stomach acids, saliva, and sweat. Diphemanil is indicated for the treatment of peptic ulcer disease, gastric hyperacidity, hypermotility in gastritis and pylorospasm, and hyperhidrosis (excessive sweating). Its mechanism involves inhibition of parasympathetic activity in smooth muscle and glandular tissue[1][4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphemanil.